Drug Trial Radar · NCT01955252
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea
Last checked: Nov 19, 2026Latest source record: Aug 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16,000
Actual
Start
Mar 2013
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Lihir Medical CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Barcelona Institute for Global Health; National Department of Health, Papua New Guinea; World Health Organization; University of Washington
- First posted
- Oct 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial that the investigators are proposing is a pilot study to determine the effect of the new WHO-yaws eradication strategy in Lihir Island (population 18,000), Papua New Guinea. New treatment policies were developed by WHO in 2012 to replace those of the 1950s. The recommended practice is to offer an initial MDA with azithromycin to the entire population, followed by resurveys every 6 months to detect and treat remaining cases.We will use serology surveys, clinical surveys and ulcer aetiology studies to measure the effect of mass azithromycin treatment on the community burden of yaws infection.
Conditions
- Yaws
Interventions
AzithromycinDrug
Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay). Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance. Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly. For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of yaws latent infectionTime frame: 42 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lihir Medical Centre
Londolovit, New Ireland Province, Papua New Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.